The Novel Serine Protease Tumor-Associated Differentially Expressed Gene-15 (Matriptase/MT-SP1) Is Highly Overexpressed in Cervical Carcinoma

Cancer

Volumn 98, Issue 9, 2003, Pages 1898-1904

  Santin, Alessandro D ^a,c   Cane, Stefania ^a   Bellone, Stefania ^a   Bignotti, Eliana ^b   Palmieri, Michela ^b   De Las Casas, Luis E ^a   Anfossi, Simone ^b   Roman, Juan J ^a   O'Brien, Timothy ^a   Pecorelli, Sergio ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

Cervical carcinoma; Matriptase; Serine protease; Tumor associated differentially expressed gene 15

Indexed keywords

SERINE PROTEINASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MATRIPTASE GENE; METASTASIS; MT SP1 GENE; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED DIFFERENTIALLY EXPRESSED GENE 15; UTERINE CERVIX CARCINOMA; UTERINE CERVIX EPITHELIUM;

ADENOCARCINOMA; ADULT; CARCINOMA, SQUAMOUS CELL; CERVIX UTERI; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE ENDOPEPTIDASES; TRYPSIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 0142243202     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11753     Document Type: Article

References (32)

1. Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta. 1987;907:191-207.
2. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327-336.
3. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 1992;10:145-155.
4. Hooper JD, Clements JA, Quigley JP, Antalis TM. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem. 2001; 276:857-860.
5. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem. 2002;48:1198-1205.
6. Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate - specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology. 2002;59:2-8.
7. Yousef GM, Scorilas A, Nakamura T, et al. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res Treat. 2003;78:149-158.
8. Diamandis EP, Scorilas A, Fracchioli S, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol. 2003;21:1035-1043.
9. Bharaj BB, Luo LY, Jung K, Stephan C, Diamandis EP. Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. Prostate. 2002; 51:35-41.
10. Diamandis EP, Okui A, Mitsui S, et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res. 2002;62:295-300.
11. Luo LY, Katsaros D, Scorilas A, et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 2003; 63:807-811.
12. Yousef GM, Fracchioli S, Scorilas A, et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol. 2003;119:346-355.
13. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem. 1999; 274:18231-18236.
14. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME, Dickson RB. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res. 1993;53:1409-1415.
15. Oberst M, Anders J, Xie B, et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol. 2001;158:1301-1311.
16. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem. 2000; 275:36720-36725.
17. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem. 2000;275:26333-26342.
18. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol. 2001;22: 104-114.
19. Tanimoto H, Yan Y, Clarke J, et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res. 1997;57:2884-2887.
20. Underwood LJ, Tanimoto H, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res. 1999;59:4435-4439.
21. Underwood LJ, Shigemasa K, Tanimoto H, et al. Ovarian tumor cells express a novel multi-domain cell surface serine protease. Biochim Biophys Acta. 2000;1502:337-350.
22. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, O'Brien TJ. Increased expression of protease M in ovarian tumors. Tumour Biol. 2001;22:11-18.
23. Santin AD, Hermonat PL, Ravaggi A, et al. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol. 1999;73:5402-5410.
24. Brand K. Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr Gene Ther. 2002;2:255-271.
25. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 1993;73:161-195.
26. Lamszus K, Jin L, Fuchs A, et al. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab Invest. 1997;76:339-353.
27. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol. 1999;71:130-135.
28. DiSaia PJ, Creasman WT. Invasive cervical cancer. In: DiSaia PJ, Creasman WT, editors. Clinical gynecologic oncology (5th edition). St. Louis: Mosby-Year Book, 1997:51-106.
29. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest. 2002;109:1519-1526.
30. Cannon MJ, O'Brien TJ, Underwood LJ, Crew MD, Bondurant KL, Santin AD. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Expert Rev Anticancer Ther. 2002;2:97-105.
31. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 2002;109:409-417.
32. Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol. 2000;165: 3797-3803.